adriana.polo2025-04-23T15:36:21+02:00Europe’s biosimilar blind spot: many biologics losing exclusivity have no competitionadriana.polo2025-04-23T15:36:21+02:00April 23, 2025|
adriana.polo2025-04-23T15:36:58+02:00Regulations, market shifts and the biosimilar void: what’s at stake?adriana.polo2025-04-23T15:36:58+02:00March 28, 2025|
adriana.polo2025-03-25T10:43:27+01:00Why are biosimilars still met with hesitation—and how can we change that?adriana.polo2025-03-25T10:43:27+01:00March 25, 2025|